Blog
RSS FeedPosted by Michael Wonder on 15 Jul 2021
Another month, another terminated appraisal of a cancer medicine
14 July 2021 - This time it is a medicine for adults and children with acute lymphoblastic leukaemia. ...
Posted by Michael Wonder on 07 Jul 2021
Enzalutamide for men with hormone sensitive metastatic prostate cancer
7 July 2021 - NICE publishes final guidance on a new indication for Xtandi. ...
Posted by Michael Wonder on 07 Jul 2021
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
7 July 2021 - Final guidance published after appeal. ...
Posted by Michael Wonder on 14 Jun 2021
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients
14 June 2021 - Bristol Myers Squibb’s immunotherapy combination Opdivo plus Yervoy has been recommended by NICE for the treatment ...
Posted by Michael Wonder on 14 Jun 2021
NICE to reassess Kyowa Kirin’s Poteligeo
14 June 2021 - NICE will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by ...
Posted by Michael Wonder on 10 Jun 2021
Astellas’ Xtandi bags NICE approval in prostate cancer
10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate ...
Posted by Michael Wonder on 08 Jun 2021
NICE recommends Tecentriq for first-line NSCLC
7 June 2021 - NICE has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer. ...
Posted by Michael Wonder on 26 May 2021
NICE terminates yet another two appraisals
26 May 2021 - This is becoming far too commonplace. ...
Posted by Michael Wonder on 20 May 2021
NICE nod for BMS’ Opdivo in advanced oesophageal cancer
14 May 2021 - The UK NICE has recommended Bristol Myers Squibb’s Opdivo for the treatment of unresectable advanced oesophageal ...
Posted by Michael Wonder on 20 May 2021
NICE turns down Janssen's Erleada
20 May 2021 - NICE has published draft guidance rejecting Janssen's Erleada (apalutamide) with androgen deprivation therapy for treating prostate ...
Posted by Michael Wonder on 19 May 2021
NICE terminates yet another appraisal of a cancer medicine
19 May 2021 - This time it is for a new medicine for patients with multiple myeloma. ...
Posted by Michael Wonder on 17 May 2021
Optimising managed access: lessons from the Cancer Drugs Fund
14 May 2021 - The desire, opportunity, and willingness to increase access to potentially life saving cancer treatments has mounted in ...
Posted by Michael Wonder on 14 May 2021
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
14 May 2021 - NICE recommends pembrolizumab for colorectal cancer patients with rare mutations. ...
Posted by Michael Wonder on 07 May 2021
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy
7 May 2021 - NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or ...
Posted by Michael Wonder on 06 May 2021
Preliminary NICE 'no' for Merck's Bavencio
6 May 2021 - NICE has issued a preliminary rejection of NHS funds for use of Merck Serono's Bavencio (avelumab) ...